Boletín de Oportunidades de Cooperación:

Biotecnología y Salud

Boletín nº 144

junio 2016

enterprise europe network
Conecte su empresa a Europa

ceseand
CENTRO DE SERVICIOS EUROPEOS PARA LAS EMPRESAS ANDALUZAS

JUNTA DE ANDALUCIA
Agencia Andaluza del Conocimiento
CONSEJERÍA DE ECONOMÍA Y CONOCIMIENTO

Comisión Europea

Índice

	traumatic neuropathy and anti-inflammatory agents in neurogenic inflammation releated diseases	
TRES20160520001	Looking for pre-diagnostic healthcare software / web platform which uses a smart electronic stethoscope's sound signal.	Technology Request

Business Offer

A Croatian producer of therapeutic textile products made of materials with thermoregulation and oxygen release properties seeks distributors or agents/representatives

Summary

A Croatian company specialized in the medical therapeutic products has developed a set of textile products with thermoregulation and oxygen release properties using Celliant yarn. The developed garments may enhance blood circulation and oxygen level in tissues up to 29%. They are made of natural textiles with using of infrared technology. The developers are looking for partners interested in commercial or distribution agreement in order to expand its business in new foreign markets.

Expiration Date 13 May 2017
Reference BOHR20160323002

Details

Description

The Croatian company has experience in creating various types of the medical therapeutic program on a natural basis. The company developed a therapeutic program, using a Celliant yarn and technologically that is one of the most advanced on the market regarding blood circulation and oxygen release in tissue. Celliant products are made of special technologicaly treated yarn which helps to convert the body temperature into an infrared light and thereby converts the energy that is otherwise lost, to the re-usable source of energy which releases the oxygen in the body, increases circulation and improves the general state of the organism. Celliant yarn is made with microscopic particles of photosensitive minerals that are woven or inserted into the fibre and fibre products by nanotechnology. Products are made with a modified optical fibre which reflects the light energy to the skin and thus relax the capillaries in the skin and the subcutaneous tissue and accelerate the blood circulation and the oxygen transfer. This process has long term effect and does not cause any side effects. Products are made of Celliant yarn in combination with different materials (wool, cotton, silver).

It is clinically proven that Celliant made products stimulate blood circulation, increases the volume of oxygen in the blood and tissue up to 29 %, and regulates the body temperature. Other effects of the therapeutics products depends on the type of product and are listed below:

Therapeutic gloves
They raise the volume of oxygen in the subcutaneous tissue and can reduce pain in the hands and wrists affected with arthritis. They may help the people with a healing wounds, including some forms of dermatitis. The gloves are designed for people with a skin problems (dermatitis, healing of ulcers). Due to the characteristics of cotton, it is recommended also to wear it during sleep. Another variant of the gloves (merino wool) is intended for the people who have problems with arthritis, rheumatism and joints. The third version (whole gloves made of Celliant yarn) is intended for recovery of the most severe skin problems (heavier burns) and for accelerating

recovery (faster entry of oxygen through the skin, quicker restoration of the skin's barrier).

Therapeutic socks
The secondary effects of the functional accessories such as merino wool may further regulate the body temperature. The addition of a silver enhances the antibacterial activity. The socks can also prevent the occurrence of a diabetic foot. Depending on the raw material, the socks are adjusted for the people who have problems with arthritis and rheumatism, diabetics, people who are in the post-operative procedures, hunters, skiers, mountain rescue service, fire-fighters, hikers, persons who are working in the extreme weather conditions, people with problems in the peripheral circulation, people with venous insufficiency (ulcer) and varicose, people in post-operative procedure of venous disease, pregnant women, athletes, recreational athletes.

Therapeutic waistband
The waistband may reduce the pain in the lower back. Also, it helps people with kidney problems. Due to the increase of the oxygen volume and stimulation of the micro circulation, the function of the kidneys under pressure can be performed much more easily than before. The waistband is designed for the people with problems in the lower back (sciatica, lumbago, discus hernia), renal patients (dialysis, transplantation), as well as people who have problems with hips, dysmenorrhoea and/or with limited mobility.

Therapeutic sleeping mask
Since the body has a recovery period during the night (restoring muscle and motor functions, protein synthesis), secondary effects can enable easier sleep, reduce headaches, sinus problems and rest tired eyes.

Via distribution services or commercial agency agreement the company seeks partners for further dissemination of their products.

Advantages and Innovations

The main advantage of the products with Celliant yarn is stimulation of blood circulation and regulation of body temperature. It is clinically proven that Celliant increases the volume of oxygen in the blood and tissues up to 29 %. Results of therapy with Celliant made products may be the reduction of pain, cramps and tingling, rapid recovery in healing of sores on the skin, etc. Products made of Celliant yarn can help people with specific health problems. For example, the therapeutic socks are for the people with diabetes, rheumatism, arthritis or for the extreme outdoor conditions (hunters, mountain rescue services, skiers) and the therapeutic gloves are for the people with skin problems and/or for the people with arthritis and psoriasis. Also, the company is offering a sleeping topper, the cushions for wheelchair users, the seating cushions and the cushions for haemorrhoids.

Company is not only realizing production of the therapeutic textile products, but also is closely working with medical personnel, diabetic associations and rehabilitation institutions. Company has experience using the infrared technology in textile production and has strong position on Croatian and Slovenian market, but also wants to expand on EU, USA, Australian and Asian market.

Stage of Development

Already on the market

IPR Status

Patent(s) applied for but not yet granted,Trade Marks

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : Yes

Client

Already Engaged in Trans-National Cooperation

No.

Languages Spoken

English
German
Croatian

Client Country

Croatia

Partner Sought

Type and Role of Partner Sought

Type of partner sought: distributors of therapeutic supplies, long term distributors connected with end users: diabetics, elderly and disabled users, medical associations.
Specific area of activity of the partner: healthcare or textile sector
Task to be performed by the partner sought: Partner will resale products under distribution services agreements or promote and sale under commercial agency agreement.

Type and Size of Partner Sought

SME 11-50,SME <10,>500 MNE,251-500,SME 51-250,>500

Type of Partnership Considered

Distribution services agreement
Commercial agency agreement

Business Offer

Italian company offers technical laboratory services and advisory for Life Sciences companies

Summary

Italian non-clinical Contract Research Organization active in the field of specific laboratory services for in vitro and in vivo systems and regulatory support services is looking for foreign partners for services and subcontract agreement. The company, with decades experience as part of an international pharmaceutical firm, gained specific expertise in small molecules, biologics, oncology,clinical support areas. Activities in the medical devices and agrochemical fields are supported.

Expiration Date 09 May 2017
Reference BOIT20160208001

Details

Description

Italian company providing technical services and scientific advisory in the field of Life Science is looking for international partners. The company is a non-clinical Contract Research Organization with more than 30 years experience serving international pharmaceutical and biotechnology companies, providing pre-clinical, biologics and small molecules services, acting as drug development partner.

The company supports all stages of the drug discovery and development process, offering integrated services, including Attrition Reducing Technologies (ART) and toxicology screening for drug candidates.
Other services offered are: investigating new drugs enabling packages; safety pharmacology; Developmental and Reproductive Toxicology (DART); PharmacoKinetics and PharmacoDynamics modelling; isotope chemistry/drug disposition; metabolite profiling and identification.
The company gained a specific know how in developing oncology products, acting as an R&D site of major pharmaceutical companies and in collaboration with important clinical oncology centres in Europe and USA.

The company also provides specific support services for clinical drug development programmes through:

• Clinical Bioanalysis services: Immunoassay based methodologies, bioanalysis for Phase I Clinical Studies; facilities for light-sensitive and cytotoxic compounds, automated sample handling, biomarker assays, support for special studies;

• Clinical Pharmacokinetic Analysis: bioequivalence studies, food effect studies; drug-drug interaction, Statistical assessment of dose proportionality, time-invariance and effect of genders, analysis and reporting of data pharmacokinetic data from Phase I/II Clinical trials;

The company offers regulatory advisory services about drug safety, pharmacology safety, Absorption Distribution Metabolism and Excretion (ADME), and bio-analysis and pharmacokinetic studies to translate new chemical entities and bio-therapeutics into novel medicines.

The firm also has a specific expertise in Medical Devices and Agrochemical fields.

The company is looking for clients active in Life Sciences sector, with a specific focus on pharmaceutical, biotech and medical devices fields, which need laboratory services for in vitro and in vivo systems. The company will offer technical services upon clients' request.

The company is looking for long term international cooperation in the form of services and subcontracting agreement.

Advantages and Innovations

The company collaborates with pharmaceutical and biotechnology companies based in European and Extra European countries managing pharmacokinetics, metabolism and toxicology issues.

The company owns specific animal facilities, which accommodate rodent and non-rodent animal species, providing services packages and integrated studies to develop new therapeutics in all therapeutic areas. Moreover they can provide specific support services to develop New Chemical Entities (NCEs) and biologics as new oncology drugs.

The company owns a specific analytical biology expertise focusing on bio-analysis and immunogenicity testing of different biological drug products, such as bioactive recombinant proteins/peptides, therapeutic monoclonal antibodies, as well as oligonucleotides and gene therapeutics, providing an extensive battery of state of the art technologies.

All these services are performed and reported in accordance with Good Laboratory and Clinical Practice (GLP and GCP) guidelines and relevant international regulation (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - ICH, European Middle East and Africa – EMEA, Food and Drug Authority – FDA). The company constantly performs internal audit.

Moreover, the company uses validated software services in accordance with the requirements stipulated by regulatory bodies.

The company has a specific expertise in Medical Devices and Agrochemical fields.

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : Yes

Client

Already Engaged in Trans-National Cooperation

Yes

Languages Spoken

English
German
Italian

Client Country

Italy

Partner Sought

Type and Role of Partner Sought

Big and small companies active in the field of Life Science, with a specific focus on pharma, biotech and medical device sector, which need specific laboratory services and regulatory advisory.

Cooperation type: Services Agreement and subcontracting.

Type and Size of Partner Sought

SME 11-50,University,R&D Institution,SME <10,251-500,SME 51-250,>500

Type of Partnership Considered

Services agreement
Subcontracting

Distributors sought for unique and new system of liquid storage management in medical field and DNA analysis

Summary

A French company specialised in laboratories and hospital diagnostics instruments has designed and manufactured a complete and unique range of systems for the liquid storage management of biological samples. It is looking for distribution agreements to increase its markets in foreign countries.

Expiration Date 23 May 2017
Reference BOFR20160314003

Details

Description

The French company designs and manufactures laboratory analysis devices for its customers involved in biotechnology, in-vitro diagnostics sectors, agrofood, environment and chemistry.

It has designed a new system to improve the liquid storage management and transport of biological, DNA samples. It looks for distributors to commercialize its new concept abroad. Currently, the company has developed reliable and in a long term distribution cooperations in different countries such as: Italy, Israel, Poland, Switzerland, South of Africa.

This medical instrumentation is designed for small to medium size laboratories...including clinical, serum and blood banks, cord blood, diagnostics, drug centers, biotechnical, veterinary environment and safety testing laboratories.

The company has developed a range of medical systems from feasibility study to small and medium series production of subassemblies and complete instruments.

Based on proven experience in microtechnology, the company has acquired for many years a know-how and technological expertise resolutely focused on laboratory instrumentation.

Its mission is to develop innovative products guaranteeing a high level of quality and reliability.

Designed for small to mid-sized laboratories and hospitals to meet ever-increasing pressures on time and productivity, the system of management of samples provides complete, reliable liquid storage management of biological samples.

The system of sample management is designed to fulfil all its clients' requirements for liquid sample management (-80°C) thanks to a complete range of products:

- An automated liquid handling robot helps the end users to transfer their laboratory samples from the primary tubes to secondary tubes and plates, guaranteeing traceability and security.

- A plate, with its integrated 2D barcode, together with the manager software, guarantees traceability using a positive identification methodology and efficient retrieval from the biobank.

The company is looking for distribution agreements with industrial companies, small and medium analysis laboratories, hospitals, clinics, care centers, biobanks, clinical, serum, blood and cord blood banks, drug centers, all medical structures involved in healthcare, DNA diagnostics, blood analysis, bio chem technologies, biotechnology, toxicology, DNA diagnostics, blood analysis, veterinary environment and safety testing.

Advantages and Innovations

Advantages regarding the company:
Security and traceability, productivity and flexibility are the main objectives and strengths of this innovative company.

Maintenance: the partners can beneficiate of free maintenance services. Elsewhere, the maintenance is easy: - air based aliquoting for minimum maintenance - easy access to internal components - custom software helps the technicians to perform rapid maintenance and calibration. Instrument is very reliable with a very high MTBF (Mean Time Between Failures).

The company can optimize the existing systems of its clients in their own organisation and accelerate their innovation, thanks to a strong expertise in the field of medical and DNA diagnostics and analysis. Moreover, the company can manufacture and commercialize the own products of its reliable partners.

The company helps its distributors in providing precise documentation, in-depth technical assistance, advice and training, highly experienced maintenance services. It works with its partners in a high proximity and confidence.

It has developed several distribution networks in different countries in a long term and reliable cooperations.

It provides very qualified services adapted to its clients' certifications and requirements.

Advantages regarding the sample management system:
- The new sample management instrument is designed to guarantee the traceability of samples, to ensure sample integrity, to improve tracking efficiency and finally to optimize freezer space in order to effectively manage the clients' biobank’s needs.

- This system manages the full lifecycle of a sample, from reception of the primary tubes to expiration or final analysis of the resulting aliquots.

- The refrigerator or freezer storage phase is also fully monitored.

- The storage software allows to save time in finding quickly the right location of samples.

- The specialists and users can beneficiate of a complete tracking and retrieval storage management s

Stage of Development

Already on the market

Profile Origin

Private (in-house) research

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : Yes

Client

Already Engaged in Trans-National Cooperation

Yes

Languages Spoken

English
French

Client Country

France

Partner Sought

Type and Role of Partner Sought

The company is looking for distributors involved in healthcare, bio chem technologies, DNA diagnostics, blood analysis, hospitals, clinics, analysis laboratories, care centers, biobanks.

This medical instrumentation is perfectly adapted to end users involved in small to medium size laboratories, including clinical banks, serum banks, blood banks, cord blood, diagnostics, drug centers, biotechnical, toxicology, veterinary environment and safety testing laboratories.

Type and Size of Partner Sought

SME 11-50,University,R&D Institution,SME <10,>500 MNE,251-500,SME 51-250,>500

Type of Partnership Considered

Distribution services agreement

Business Offer

UK healthcare company seeks European distributors for drug free pain management device

Summary

This innovative UK healthcare company has manufactured and retailed pain management products for over 20 years. Now this company is looking for distribution of a Class IIa pulsed electro-magnetic field therapy device for pain management within Europe and worldwide.

Expiration Date 13 May 2017
Reference BOUK20160407001

Details

Description

This UK based healthcare company manufactures and retails an industry leading Class IIa medical device using electromagnetic field therapy for pain management.
The device was initially developed for use in hospitals to reduce the chronic pain associated with conditions such as arthritis. It has since been shown to relieve chronic pain derived from a range of conditions whilst being completely drug free and without side effects.
The company has worked in collaboration with leading scientific research laboratories to advance and develop this product to the highest standard and it has been assessed and certified as meeting the requirements of directive 93/42/EEC on medical devices.
The device itself is portable, battery operated and is small enough to fit in the hand of the patient. It comes complete with a velcro strap and additional batteries.
The company has a large existing UK customer base through multiple routes to market achieving over 500,000 unit sales including NHS pain clinics throughout the UK. The company is looking to further the success of this device by increasing their distribution throughout Europe and worldwide by way of distribution agreements.

Advantages and Innovations

- Attractive margins for distribution
- Class IIa medical device with CE marking to the medical device directive.
- Clinically trialed at the King's College Hospital, London,UK
- Large potential customer base - over 55's
- Proven track record of sales
- Logistics infrastructure in place.

Stage of Development

Already on the market

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : Yes

Client

Already Engaged in Trans-National Cooperation

Yes

Languages Spoken

English

Client Country

United Kingdom

Partner Sought

Type and Role of Partner Sought

The Company is looking for European and worldwide distributors that have existing links to health organisations, pharmacies, hospitals, private clinics or direct to the end user to sell this medical device under a distribution agreement.
The UK company is willing to work closely with the right partner throughout the process which includes marketing support and product training.

Type of Partnership Considered

Distribution services agreement

Attachments

Capture 1.JPG


7.8Hz
3Hz
20Hz
OFF
Low
Battery

EUREKA or Joint R&D partner sought on remote telehealth

Summary

A Korean SME specializing in telehealth has developed an all-in-one telehealth monitoring gateway which collects, saves and transfers vital sign measurement data from medical sensors to professionals for diagnosis. This technology transfers to healthcare service servers for professionals' analysis and monitoring. The company is looking for R&D partners to participate in bilateral or Eureka projects, especially software and commercialization partner.

Expiration Date 06 May 2017
Reference RDKR20160504001

Details

Description

Remote telehealth and telemedicine service are increasingly pandemic in a world where care services like hospital, clinics and doctors are in short supply, their costs of keeping healthy are skyrocketing and communities lack access to care.

A Korean SME specializing in telehealth has developed an all-in-one telehealth monitoring gateway. This telehealth system offers users or patients better access to their health record and allows caregivers to remotely monitor the vital measurement data via internet. This all-in-one device aggregate data from the medical sensors of PAN area in encrypted digital format and incorporate it into a digital record that can be transmitted securely. Users, patients, family, caregivers and caregiver's professionals are able to analyze the health record remotely and respond efficiently.

This telehealth gateway provides multi functions to use easily. It is comprised of microphone and HD camera for video telephony and can be used through USB, Bluetooth and Ethernet. Device interface is satisfied with continua CDG and other international standards (e. g. IEEE, CE). Users such as patients, caregivers and family receive encryption of stored and transferred data from common model for security, management or enforcement behavior. This technology provides HL7V3 messaging (Healthcare Level 7 V3 messaging) through medical devices.

Desire partners are the companies in the industrial fields of digital healthcare and health service S/W development, especially in WAN(Wide Area Network) and HRN(Health Record Network) interface.

This company expects to propose to Joint R&D project with German or France. The expected duration to complete both projects is two years. The deadline of 3rd German-Korean call for proposals for joint R&D projects is Jun 7, 2016. EOI deadline is May 15th. Other deadline of Korea-France call for proposals for joint R&D projects is Aug 31, 2016(call 2016-2). Others' EOI receive by July 15th.

Advantages and Innovations

* Features of telehealth gateway
- Stand-alone multi-function telehealth gateway
- User friendly wide touch LCD display
- Vital sign collecting from sensors, and transferring to servers
- Personalized health care information/function support
- Rich and flexible service for a variety of places such as home, hospital and nursing home
- Video conferencing for remote connecting patients and doctors

* Wired/wireless network interface and sensor devices connection through Bluetooth and USB(Universal Serial Bus).

* Satisfied with industrial standard(e.g. IEEE 11073, (Federal Communications Commission), FDA(Food and Drug Administration), EN6060-1-1, CE).

* Connected to medical sensor such as blood pressure monitor, blood glucose meter, weighing scale, O2 Saturation(SPO2), thermometer, ECC/EKG(ElectroCardiogram) and heart rate.

Stage of Development

Proposal under development

IPR Status

Patent(s) applied for but not yet granted

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : Yes

Client

Already Engaged in Trans-National Cooperation

No.

Languages Spoken

English

Client Country

South Korea

Partner Sought

Type and Role of Partner Sought

- Type of partner sought : Large company / SME

- Specific area of activity of the partner : Digital Healthcare / Health service S/W development

- Task to be performed : Remote health care server/service software development

Type of Partnership Considered

Research cooperation agreement

Attachments

Diagram.png



Novel treatment of oxaliplatin-induced neurotoxicity in the peripheral nerves.

Summary

A regional Cypriot research institution in the field of neurology and genetics developed a new approach for treating oxaliplatin-induced neuropathy. Recent in-house research, including extended lab tests, showcased that the co-administration of octanol and oxaliplatin blocks the affectation of the peripheral nerves. The research team is seeking pharmaceutical companies for a financial and/or license agreement to further develop the treatment.

Expiration Date 16 May 2017
Reference TOCY20160509001

Details

Description

The research team of a Cypriot research institution developed a novel treatment of the oxaliplatin-induced neurotoxicity in the peripheral nerves. Oxaliplatin is used extensively as a first-line drug in gastrointestinal cancer chemotherapy, in particular metastatic colorectal cancer, although its mechanisms of action remain poorly understood. The major dose-limiting toxicity of oxaliplatin is peripheral neuropathy that can manifest in over 60% of treated patients. The major cause for this oxaliplatin peripheral neuropathy is the hyperexcitability in the peripheral nerve fibres. This effect has been investigated with various methodologies but there was not a conclusive solution to the problem until know. The exact mechanism by which oxaliplatin causes neurotoxicity has remained uncertain, despite extensive previous studies, and currently there is no effective prevention or treatment for this important and frequent dose limiting complication of a common cancer therapy.

In order to study the mechanism cause this oxaliplatin-induced neuropathy, the research team performed ex vivo electrophysiological and histological studies using the isolated sciatic nerve of mouse. When the sciatic nerve preparation was exposed to oxaliplatin, a neurotoxic effect was occurred. This severe oxaliplatin effect was caused by hyperexcitation of individual nerve fibres and is the likely mechanism leading to the acute neuropathy in patients during intravenous application of oxaliplatin.

As a solution, the research team hypothesized a direct functional interplay between gap junction channels and voltage-gated potassium channels (VGKCs) may mediate the oxaliplatin-effect. Specifically, oxaliplatin may cause forced opening, causing accumulation of extracellular K+ generated during axonal activity, which in turn causes indirectly malfunction of VGKCs and prolongation of the repolarising phase. After testing, the team confirmed that octanol compensates for the effect of oxaliplatin by blocking the forced opening of these hemichannels allowing their proper function. Comparing to other gap junction blockers, octanol is safe and has been already used in clinical trials for essential tremor. When these findings were reproduced in vitro, oxaliplatin opens gap junction hemichannels and accordingly this effect was blocked by octanol in a dose dependent manner. Additionally, the morphological examination of the sciatic

nerves indicated that initially functional changes in peripheral nerves including hyperexcitability are not accompanied by structural damage of the nerve. Finally, any morphological changes caused by prolonged exposure to oxaliplatin could be prevented by co-administration of octanol. Thus, the research team propose co-administration of octanol as a prevention of oxaliplatin induced acute and chronic neuropathy manifestations.

The research team is seeking for pharmaceutical companies for finance and/or license agreement to further develop the treatment including clinical trials and drug development in order to be available for market distribution.

Advantages and Innovations

Compared to previous studies, our study provides a novel mechanistic explanation for the observed oxaliplatin neurotoxicity and proposes an effective neuroprotective approach. The use of the gap junction blocker octanol against oxaliplatin-induced neurotoxicity (OIN), as suggested by our findings, overcomes the problems of preventing OIN, since we propose a completely innovative mechanism and show highly effective blockade of the oxaliplatin effect, both functionally and morphologically. Octanol can be readily used in clinical practise as it has a known safety and tolerability profile as previous clinical trials for other disorders showed, and shows the potential for full reversal of the OIN, both at electrophysiological as well as at the morphological level.
Numerous previous attempts to reduce OIN have been reported, using several potential neuroprotective substances. However, none of those agents proved to be effective in preventing OIN. Our study clearly supports the potential for the clinically relevant gap junction blocker octanol to efficiently prevent OIN by blocking Cx32 and Cx29 channels, effectively preventing oxaliplatin effects ex vivo and in vitro.

Stage of Development

Under development/lab tested

Comments Regarding Stage of Development

Treatment tested in preclinical experimental in vitro and ex vivo models. Not yet tested in vivo.

IPR Status

Patent(s) applied for but not yet granted

Comment Regarding IPR status

A PCT application has been filed.

Profile Origin

Private (in-house) research

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : Yes

Client

Already Engaged in Trans-National Cooperation

Yes

Languages Spoken

English
Greek

Client Country

Cyprus

Partner Sought

Type and Role of Partner Sought

Pharmaceutical or other company with expertise in drug development from preclinical to clinical trials stage, that can acquire the license for further exploitation and clinical development of the invention in order to develop a drag for the market.

Type and Size of Partner Sought

SME 11-50,SME <10,SME 51-250

Type of Partnership Considered

License agreement
Financial agreement

All-in-one patient vital sign monitoring gateway that can interoperate with medical sensor devices

Summary

A Korean SME specialized in telehealth offers a remote telehealth monitoring gateway. The company collects vital signs from the medical sensor devices and transfers the records. This technology provides all-in-one healthcare solution satisfying industrial standards solution of healthcare (e.g. IEEE 11073). The company is looking for a partner for commercial agreement with technical assistance, research cooperation agreement and technical cooperation.

Expiration Date 16 May 2017
Reference TOKR20160510001

Details

Description

Recently, Information & Communication Technologies (i.e. internet, IT, etc) have been converging into healthcare industries. With this technologies, patients are able to receive healthcare services such as prevention disease, diagnosis, treatment, and follow-up care whenever and wherever they need.

The internet has been combined with information communication technology based on IT. This technology is called u-healthcare that provides healthcare and medical service. The patients can receive service for the prevention and control of disease, treatment and follow-up anytime and anywhere without visiting hospital. A Korean SME runs a u-healthcare solution business based on telehealthcare.

This Korean SME's telehealth system offers users or patients better access to their health record and allows caregivers to remotely monitor the vital measurement data via the internet. This all-in-one device aggregate data from the medical sensors of PAN(Personal Area Network) in encrypted digital format and incorporate it into a digital record that can be transmitted securely. Users, patients, family, caregivers and caregiver's professionals are able to analyze the health record remotely and respond efficiently.

* Features of telehealth gateway
- Multi-function standalone telehealth monitoring system
- User friendly touch-screen and color display
- In-built speakers, microphone and HD camera for video telephony
- Ethernet and WIFI to transfer measurement record
- Bluetooth Smart ready to collect vital signs of users
- Wired medical sensors connection through USB
- Encryption of stored and transferred data

* Communication profiles and standard
- It complies with all requirements of Continua and other international standards(IEEE, CE, etc.).

* Service architecture of healthcare device
- Service interface that complies with continua CDG
- Personal healthcare device includes vital measurements that the sending and receiving entities agreed are relevant to the user's condition
- Please refer to attached picture

* Encryption of stored and transferred data
- The data interface complies with Continua CDG(Continua Design Guidelines) 2015[H.812]
- Common message exchange behavior : The trust relationship details are determined by policy
- Common security model for REST based CDC(Centers for Disease Control) implementations : All interactions with the authorization and resource server are performed in a secured session using [IEEE RFC 4346]
- Consent management behavioral model : Transactions related to the consent management use cases
- Consent enforcement behavioral model : Encryption for uploaded consent

* HL7V3 messaging →HL7 (Healthcare Level 7) V3 messaging
- Interoperability
-It complies with all requirements of Continua and other international standards
- Immediately connect with Continua-certified medical devices
- Interoperability with the medical devices
- Solution for digital healthcare services
- Easy to connect with medical devices conveniently
- Collects and stores the medical records aggregating from the medical devices and manages them consistently
- Supports HL7(standard used in transferring medical record)
- Supports Web service standards for data interchange
- Interface specification

Advantages and Innovations

* Healthcare All-in-one Solution
- Stand-alone multi-function telehealth gateway
- User friendly wide touch LCD display(Liquid crystal display)
- Vital sign collecting from sensors, and transferring to servers
- Personalized health care information/function support
- Rich and flexible service for a variety of places such as home, hospital and nursing home

* Easy Digital Healthcare system
- Easy to connect with medical sensor devices conveniently
- Easy to use; simple self- measurement and automatically transmits data
- Wired/Wireless network support
- Sensor devices connection through Bluetooth and USB

* Comply with industrial standards
- Fully comply with Continua(IEEE 11073) standard
- FCC(Federal Communications Commission), FDA(Food and Drug Administration) certified
- EN60601-1 and CE certified
- Spill/Dust Resistant and Easy cleanable enclosures

* Available sensor lists
- Blood pressure monitor
- Blood Glucose meter
- Weighing scale
- O2 Saturation(SPO2)

- Thermometer
- ECG/EKG(ElectroCardiogram)
- Heart rate

Stage of Development

Already on the market

Comments Regarding Stage of Development

The previous product of a telehealth gateway has been launched already to demonstrate for telehealth trial and commercial service in the US market.

IPR Status

Patent(s) applied for but not yet granted

Comment Regarding IPR status

Korean patents and PCT applied for but not yet granted.

Profile Origin

COSME

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : Yes

Client

Already Engaged in Trans-National Cooperation

No.

Languages Spoken

English

Client Country

South Korea

Partner Sought

Type and Role of Partner Sought

- Type of partner sought : Large company / SME
- Specific area of activity of the partner : Digital Healthcare / Health service
- Task to be performed : Provides remote health service using this monitoring gateway

Type and Size of Partner Sought

SME 11-50

Type of Partnership Considered

Commercial agreement with technical assistance
Technical cooperation agreement
Research cooperation agreement

Attachments

Service architecture.png



Advanced robotic needle guidance platform for microinvasive interventions

Summary

An Austrian SME is offering an image-guided medical robotic platform for interventional radiology and related fields. A robotic positioning unit allows sub-milimetric needle positioning and angulation and performs high precision guidance control by a handheld control unit. The company is open to a variety of partnerships including technical, research, commercial or license agreement.

Expiration Date 12 May 2017
Reference TOAT20160509001

Details

Description

Microinvasive surgical procedures are gaining more and more importance in medicine due to their proven effectiveness and benefits for patients, hospitals, insurance companies and governments. Nevertheless interventional radiology is technologically still very challenging and most physicians still puncture "free hand" because traditional guidance solutions still lack in efficiency and accuracy.

The Austrian SME is a highly specialized device manufacturer and focused on developing innovative robotic solutions for microinvasive interventions. The technology proposed by the Austrian SME is a new modular guidance platform for interventional radiology and related fields.

The advanced robotic needle guidance platform supports the interventionalist in reaching the clinical target and offers new benefits to patient safety and optimized procedural outcome. Main-components are a 4 degree of freedom (DOF) robotic positioning unit which allows sub-millimetric needle positioning as well as angulation and a control unit which is operated by a cable connected handheld device. The passive macro positioning unit and different table adapters allow various setups of the system around the patient in the region of interest by keeping maximum rigidity. The needle guide set provides disposables that ensure precise & sterile needle guidance. Planning of the intervention is based on digital image data processing in intra-operatively use of different kinds of sources, like CT (computed tomography) or 3D-fluoroscopy.

Unique key features:
- high accuracy (relative: 0.02 mm, absolute: 0.1 mm)
- small and lightweight
- redundant emergency release
- modularity and compatibility with other devices
- parallel kinematics: 2x2 DOF plus sensor
- latest interface technology
- direct coupling to table/frame

The Austrian company is looking for industrial or research partners for further development under technical cooperation agreement or research agreement. The SME also seeks private and public medical institutions already running or planning to run micro invasive procedures for introduction and implementation of the system under a commercial agreement with technical assistance or license agreement. The company is open for other possible agreements with research institutions and companies depending on the local healthcare standards and regulations.

Advantages and Innovations

The robot needle guidance platform has the following unique features:
high system accuracy
best safety standards
modularity and setup flexibility
intuitive and fast use
latest interface technology
maximum mechanical stability/compatibility

Advantages for the physicians:
Reduced radiation exposure
Simple, safe and accurate targeting
Less risk and stress during interventions
Compatible with existing imaging devices

Advantages for patients:
Higher precision
fewer side effects
faster recovery
better clinical outcomes

Advantages for healthcare institutions/hospitals:
higher safety standards
higher patient throughput
better cost-benefit-ratio
safer work environment

Stage of Development

Already on the market

IPR Status

Secret Know-how,Patents granted,Trade Marks

Comment Regarding IPR status

Patents granted in Europe, USA, Japan and Canada

Profile Origin

Eurostars

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person
María Fernández Santa Cruz Campos

Email
maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : Yes

Client

Already Engaged in Trans-National Cooperation

Yes

Languages Spoken

English
German

Client Country

Austria

Partner Sought

Type and Role of Partner Sought

The Austrian SME is primarily looking for public healthcare institutions who wish to integrate this novel technology in their programs through commercial agreement with technical assistance.

The company is also interested in working with medical companies to enable hospital introduction and implementation of the technology under license agreement.

The Austrian company seeks industrial or research partners for co-development of the technology under a technical cooperation agreement or research agreement.

The SME is open for other possible agreements depending on the national healthcare standards and regulations of the interested partner country.

Type of Partnership Considered

License agreement
Commercial agreement with technical assistance
Technical cooperation agreement
Research cooperation agreement

A Croatian university is looking for licensing for the functional endoscopic sinus surgery training model

Summary

A Croatian university has developed a training model for functional endoscopic sinus surgery and teaching anatomy of sinuses. The model contains of 15 coronary slices allowing training of detailed surgical procedure. Currently the training model has been developed as a functional prototype and protected as a registered design and trademark in EU and USA. The university is looking for the EU partner for licensing-in the technology and for distribution of finished product.

Expiration Date 04 May 2017
Reference TOHR20160218001

Details

Description

A Croatian university has developed a training model for functional endoscopic sinus surgery. The model has been developed by a multidisciplinary team consisting of professors and surgeon from School of Medicine and Technical faculty. It contains 15 coronary slices with several anatomic regions included (i.e. maxillary sinus, ethmoidal sinus, sphenoid sinuses etc.). The functional prototype of the product has been tested with very good results and the targeted population (students) gave excellent feedback about the usefulness of the model. The model has been developed in several CAD/CAM systems with additive manufacturing technology. The application fields can be sinus surgery model for teaching otolaryngologists or model for teching anatomy in schools of medicine etc.
The subject of the offer is licensing of IP for the production of the model. The ideal partner should have the adequate technology to produce the model and should be already active in production of medical models for training or has other production related to medical tools (such as Surgical instrumentation and equipment). A Functional prototype is available together with the manual in English language. The packaging of the model has also been developed.

Advantages and Innovations

The training model has been produced in high resolution which is suitable for medical practitioners – surgeons and educators. It is an authentic replica of a human head captured with CT medical equipment and modeled and split in 15 slices. The shape of sinus holes in slices changes with each slices from frontal part of head towards back side. Each slice can be removed or replaced with new one if damaged. For the purpose of training of Otolaryngologists in nose surgery, the model consist of flexible parts, hard parts imitating head bone and other very thin that represent sensitive parts in structure of a head. That gives advantage to the model over other models developed and offered on the market which doesn't show this specific perspective for medical students with sensitive change in size and shapes of sinus holes. For teaching sinus surgery techniques, this model gives quite realistic perspective comparing to

other solutions on the market that use inadequate materials for sinus surgery training or are focused on virtual simulation.

Stage of Development

Prototype available for demonstration

Comments Regarding Stage of Development

The model for teaching anatomy is already finished and ready for first series production. The model for teaching functional endoscopic sinus surgery is in final stage of development and will be ready for market in next 3 months.

IPR Status

Design Rights,Copyright

Profile Origin

Private (in-house) research

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : Yes

Client

Already Engaged in Trans-National Cooperation

Yes

Languages Spoken

English
Croatian

Client Country

Croatia

Partner Sought

Type and Role of Partner Sought

-Type of partner sought: Producers of training or teaching models in field of medicine or producers of surgeon instrumentation in field of otorhinolaryngology
- Task to be performed: License for production and sales

Type and Size of Partner Sought

SME 11-50,SME <10,>500 MNE,251-500,SME 51-250,>500

Type of Partnership Considered

License agreement

Technology Offer

The technologies of innovative wound dressing, research cooperation and financial resources are sought.

Summary

A Lithuanian University has developed new biopolymer-based wound dressings in film or sponges form targeted for treating of different kind of wounds. The technologies are developed at laboratory scale. Research cooperation and financial resources are sought.

Expiration Date 20 May 2017
Reference TOLT20160503001

Details

Description

Recently, a new generation of wound dressings has been extensively developed. Dressings made of new forms such as sponges, films and hydrocolloids have been developed together with new functions. Modern bandages not only protect the wound from infection, but as well promote the healing process, irrigate the wound, absorb the wound secretions, achieve the desired pH of the wound medium, stimulate the necessary growth factors and carry active compounds into the wound. Therefore, it is very important to perform a variety of chemical investigations.
Scientists at a Lithuanian University have developed new biopolymer-based wound dressings They are prepared from natural, biocompatible, non-cytotoxic polymers, such as regenerated cellulose, sodium alginate, pectin, hydroxyethylcellulose as well as hyaluronic acid by means of different techniques. The materials proposed are targeted for treating of different wounds. In a case of burn or open wounds transparent films from regenerated cellulose (non-adherent and non-absorbed) and hyaluronic acid (totally absorbed) have been developed. For chronic wounds with high level of exudate sponges-like dressings are prepared. For deep wound, for example for teeth cavities, resorbable sponges have been developed. The physical-chemical characteristics, such as exudate absorption capacity, water vapour permeability, adhesion to wound surface, as well as mechanical properties meets the requirements for wound dressings. Also various active compounds, like antibiotics, flavanoids, povidone-iodine, furaciline were immobilized into the dressings.
The University is looking for:
- research cooperation with other universities and R&D intitutions, whch are working in biomedical field;
- investors for financial resources for in vitro and in vivo trials.
- companies for futher development of the products.

Advantages and Innovations

A wide variety of wound dressings:
- transparent cellulose hydrogel sheets which possess low bioadhesion and a high moisture content are promising wound dressings for burn wounds, cuts, scratches and abrasions;
- transparent fully resorbable hyaluronic acid films are promising for burn wounds;
- sponges from the mixture of water soluble biopolymers possess a high liquid absorption capacity and good blood clotting ability; thus, these sponges could be applied as wound dressings for exuding and bleeding wounds;
- hyaluronic acid sponges are resorbable, thus could be used in deep wound without their removing.

All prepared dressing are not toxic, are not cytotoxic, are biocompatible.
Various active compounds, like antibiotics, flavanoids, povidone-iodine, furaciline, silver nanoparticles could be easily immobilized into the dressings.

Stage of Development

Prototype available for demonstration

Comments Regarding Stage of Development

Development stage: The prototypes have been successfully prepared and tested in lab.

IPR Status

Secret Know-how

Profile Origin

Other

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : Yes

Client

Already Engaged in Trans-National Cooperation

Yes

Languages Spoken

English
Russian
Polish

Client Country

Lithuania

Partner Sought

Type and Role of Partner Sought

Type of the partner sought:
- universities and R&D institutions, which are working in biomedical field, for research cooperation;
- investors for financial resources for in vitro and in vivo trials.
- companies for further development of the products.
Research cooperation, license and financial agreements are sought.

Type and Size of Partner Sought

SME 11-50,University,Inventor,R&D Institution,SME <10,251-500,SME 51-250

Type of Partnership Considered

License agreement
Financial agreement
Research cooperation agreement

Novel therapeutic target for restoring leukocyte function in Chronic Kidney Disease (CKD) patients

Summary

A technology transfer office in Germany (Bavaria) represents a known German university. Scientists of its Department of Anaesthesiology were capable of restoring host defense and pathogen clearance in mice with chronic kidney failure (model for Chronic Kidney Disease (CKD) patients) and thereby significantly improving their survival by applying a FGF23 (fibroblast growth factor 23) neutralizing antibody. They are looking for licensees or partners for further development.

Expiration Date 03 May 2017
Reference TODE20160303002

Details

Description

A German university represented by a technology transfer office in Bavaria has been researching in chronic kidney diseases (CKD), which is a common condition in developed countries. Little information is available about the mechanism how Chronic Kidney Disease affects host defense. Despite the availability of conventional infection therapy (including antibiotics), infection-related hospitalizations contribute substantially to excess morbidity and mortality in CKD, and infection is the second leading cause of death in this population. There is thus an urgent need for novel means and methods in treating CKD, and in particular for treatment and prevention of infection in CKD. It is the object of the present invention to comply with this need.

It was shown in a mouse model that FGF23 (fibroblast growth factor 23) contributes considerably to the reduction of functional efficiency of the immune system commonly observed in chronic kidney disease patients. Specifically, FGF23 was found to inhibit leucocyte recruitment to sites of infection, leading to an impaired clearance of pathogens from the body and increased mortality. Surprisingly, it was found out that different FGF23 inhibitors were capable of restoring host defense and pathogen clearance, thereby significantly improving survival. Moreover, it could be shown that FGF23 affects different leucocyte functions, including recruitment to infected tissue, adhesion, ICAM-1 (Intercellular Adhesion Molecule 1) binding (and rolling velocity), superoxide production, as well as integrin-dependent phagocytosis and transendothelial migration.

It can therefore be envisioned that FGF23 inhibitors exert their beneficial effects by restoring these leucocyte functions that are critical to host defense during infection.

A partner is searched for further development of FGF23 inhibitors as therapeutics for enhancing immune defense in CKD patients.

Advantages and Innovations

With this new knowledge it is possible to develop therapeutics for restoring leukocyte function in Chronic Kidney Disease patients and reduce infections in CKD patients.

Stage of Development

Under development/lab tested

Comments Regarding Stage of Development

Tested in vivo in CKD animals (mice)

IPR Status

Patent(s) applied for but not yet granted

Comment Regarding IPR status

A first patent application has been filed for Luxemburg. Patent filing under PCT is planned.

Profile Origin

National or Regional R&D programme

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : Yes

Client

Already Engaged in Trans-National Cooperation

Yes

Languages Spoken

English
German

Client Country

Germany

Partner Sought

Type and Role of Partner Sought

Type of Partner sought:
The Partner should be working in the field of chronic kidney disease therapies or in the field of prevention of infection.

Specific area of activity of the Partner:
Development and production of products for treatment and prevention of infection in chronic kidney disease.

Task to be performed:
The partner should be able to develop a product for treatment and prevention of infection in chronic kidney disease out of the given information.

Type and Size of Partner Sought

SME 11-50,University,R&D Institution,SME <10,>500 MNE,251-500,SME 51-250,>500

Type of Partnership Considered

License agreement
Technical cooperation agreement

Attachments

M0216_Fig1.jpg



Fig. 1 Survival curves of sham and CKD animals treated with isotype or FGF23 neutralizing antibody (Ab). * p <0.05

In vivo testing platform for biomedical research

Summary

A German SME offers a range of services around small and big laboratory animals according to international standards (e.g. FELASA) on the basis of technology or contract research agreements for preclinical studies and medical devices research and development. Services agreements, technology cooperation and subcontracting in European research and innovation projects is also possible.

Expiration Date 06 May 2017
Reference TODE20160420001

Details

Description

The German SME was founded out of the University of Mainz in 2004. Since then it is a service provider for research-based pharmaceutical companies, biotech companies, medical-biological research institutions and medical devices manufacturers.
The basic idea is using appropriate and high-quality animal models, accomplish facts and generate reproducible data. Professionals are forming a team that has extensive experience in animal husbandry and breeding, diagnostics, and pharmacology and pathology.

The core competencies of the company cover the fields of diagnostics of a complete health monitoring service for laboratory animals, the production of diagnostic monoclonal and polyclonal antibodies, and pharmaceutical and toxicological studies following the guidelines of good laboratory praxis (GLP).

The company is ready to offer the following tasks to clients within services agreements, on a "fee-for-service" basis. Participants of European research projects are welcome to outsource in-vivo studies by subcontracting.

Preclinical studies are performed in vivo according to standard methods or are developed according to the customers needs using tailor-made methods and models. A large animal unit and surgical facility enables a broad range of studies, such as implant, cardiovascular, neonatal and pharmacokinetic studies. The facility house allows keeping of up to 25 pigs.

The following services are offered in details:

1) Antibodies and assay development

The custom antibody services include peptide design, syntheses, labelling and conjugation, monoclonal and polyclonal antibody production, purification and immunoassay development. Antibody generation is carried out via:

• peptide immunisation
• DNA immunisation

• monoclonal antibodies in mouse and rat
• polyclonal antibodies in mouse, rat and guinea pig
• immunisation in genetically modified animals is possible according to S1 security prescriptions.

Tailor-made antibody based assays are developed, tested, evaluated and delivered as microplate based test systems for high throughput screening.

2) Preclinical research

The company conducts a wide variety of reproducible and comprehensible in vivo studies by using own laboratory animals according to the needs of the customers. The services include:
• toxicological studies according to GLP standard
• pharmacological studies
• pharmacokinetics
• transdermal tests in pigs
• medical device testing (including histology/X-ray or clinical chemistry)
• therapeutical studies
• tumor models

3) Diagnostics

Health monitoring of laboratory animals service following the recommendations of FELASA include:
• serological tests (ELISA)
• direct antigen test (RT-PCR/PCR)
• parasitology
• pathology (Histopathology)
• cytology
• microbiological tests (differentiation, antibiogramm)
• coagulation screening from blood samples
• clinical chemistry for different species (mice, rats, dogs, pigs).

4) Studies in a large animal unit

Implant Studies, e.g. oesophagal stents and implants, tracheal stents, urethral catheters;

Dermal Studies, e.g. wound dressing, wound healing, pharmacocompability, cardiovascular studies, heart catheters, blood vessel catheters and stents, ECG;

Neonatal studies, EEG;
Pharmacokinetic studies

Current and Potential Domain of Application:

• pharmaceutical Research and Development (oncology, neurogenerative diseases): in vivo preclinical testing
• chemical industry: in vivo toxicological testing (REACH)
• medical device testing, in vivo
• food microbiology
• husbandry of laboratorial animals
• development of antibody-based diagnostics

Advantages and Innovations

The companies' expertise in veterinary medicine and the facilities of keeping small and big laboratory animals enables them to offer an exceptional broad variety of pharmacological research services that are not very common for an SME.

In details the advantages for the clients and partners are:

•Essential in vivo research is realised in-house, and therefore ensures cost-effective service and a direct transfer.

Operating rooms for small and big animals

•Veterinary surgeon expertise allows animal health monitoring services within own research projects and also as external service not common in competitive offers.

•A large variety of pharmacological and biomedical research and development services is provided by using both standardised and tailor-made methods according to the customers' needs.

Stage of Development

Available for demonstration

IPR Status

Secret Know-how,Patents granted,Other

Profile Origin

Private (in-house) research

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : Yes

Client

Already Engaged in Trans-National Cooperation

Yes

Languages Spoken

English
German

Client Country

Germany

Partner Sought

Type and Role of Partner Sought

- Type of partner sought:
pharmaceutical industry and research organisations, biotechnology companies and research organisations, chemical industry, medical devices development.

- Specific area of activity of the partner:
The ideal partner should be active in drug or medical devices development, diagnostic development.

- Task to be performed by the partner sought:
The partners or clients may deliver:
targets for antibody development, lead substances for preclinical in vivo testing, chemical substances for in vivo toxicological testing.

Type and Size of Partner Sought

SME 11-50,University,R&D Institution,SME <10,>500 MNE,251-500,SME 51-250,>500

Type of Partnership Considered

Services agreement
Technical cooperation agreement
Research cooperation agreement

Primers, planning of tests, measurement of gene expression

Summary

A microbial biotechnology research group of a Hungarian university conducts a research activity which can be utilized in health and agricultural biotechnology and diagnostic services. The real time Polymerase Chain Reaction measurements are applied multifaceted in the development of medical materials and processes or during the detection of infections. With their system they would cooperate within the frameworks of research agreements and/or they would provide research services for them.

Expiration Date 30 May 2017
Reference TOHU20160502002

Details

Description

The Polymerase Chain Reaction (PCR) measurement is a special area of a microbial biotechnology research group of a Hungarian university.

The PCR measurement is an amplification of a special, selected DNA sequence with repeated enzymatic reactions, within in vitro circumstances. The amplification (multiplication) of DNA fragments used for DNA sequencing had been possible for long time only in living cells with the help of so called vectors (in bacteria, in yeast). Contrast to this the invention of polymerase chain reaction (PCR) created new possibilities in the molecular diagnostics, it revolutionized the gene technology. With its application any known sequence DNA region can be manufactured in high quantity (can be amplified). With the help of PCR technique, even a DNA piece, which is present only in one copy, can be multiplied, while for the previous methods (cloning) even in the beginning a larger amount of isolated DNA was necessary. The biggest advantage of the PCR is its enormous ability of multiplication. With its application those tests can also be conducted where very small amounts of DNA are available, either it is a diagnostic test, identification of a person during a crime or the implementation of a research project.
The development of a quantitative real-time PCR (qRT-PCR) methods makes it possible that a given molecular discrepancy can be determined not only qualitatively, but quantitatively both in the level of DNA (copy number) and RNA (gene expression).

Areas of use:
- Melting point analysis for the analysis of PCR products
- Quantitative detection of microorganisms
- Testing the efficiency of drug treatments
- Analytics of allergens
- Checking, clarification of micro acid tests.

Equipment:
- Agilent 2100 bioanalyzer system based on microfluid technology for the determination of the

size, quantitative and qualitative indicators of DNA, RNA and proteins.
- High-speed end point, gradient and real-time PCR devices.
- StepOne and StepOne plus (ABI).

The Hungarian research group expects its partners - representing the public or the economic sector - to join the development of the topics mentioned below.
The group looks for cooperation for the following research areas within the framework of service and/or research agreements:
- Molecular level study of disease processes caused by microbial infectious agents
- Structural and functional analysis of microbial genomes
- Production, accumulation, mechanism of action and detoxification of mycotoxins.

Advantages and Innovations

Infinite number of copies can be made on random DNA template
Possibility of unique DNA fragmentation test
It collects the data from the beginning till the end of the amplification.
Increased sensitivity
Requires less samples
Better resolution

Stage of Development

Already on the market

IPR Status

Secret Know-how

Profile Origin

National or Regional R&D programme

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : Yes

Client

Already Engaged in Trans-National Cooperation

Yes

Languages Spoken

English
Hungarian

Client Country

Hungary

Partner Sought

Type and Role of Partner Sought

The Hungarian research group intends to make its offer to R+D institutions operating in the field of manufacturing of pharmaceuticals or in the field of microbiology, or even in the field of criminal prosecution and forensic science.
The group seeks partners who intend to use the services or looks for research cooperation.
Within the frameworks of an services agreement, contractor provides research services for their partners who implements research projects.
Within the frameworks of the research cooperation, the group seeks partners, who:
- intend to develop technologies, or
- intend to develop further its technology, or
- seek this type of service to operate their innovative technologies.

Type of Partnership Considered

Services agreement
Research cooperation agreement

Potent heterocyclic derivative compounds analgesics in traumatic neuropathy and anti-inflammatory agents in neurogenic inflammation releated diseases

Summary

A Hungarian university developed potent heterocyclic derivative compounds with somatostatin receptor 4 and somatostatin receptor 1 antagonist and several type of kinase inhibiting effects, proved to be effective against neurogenic inflammations and neuropathic pain in rodents. Identified as new drug candidates for the prevention/treatment of acute neurogenic inflammation and/or neuropathic hyperalgesia. Partners for research cooperation, joint development and out-licensing are welcome.

Expiration Date 20 May 2017
Reference TOHU20160426001

Details

Description

This is an offer of a Hungarian university dealing with research in the field of neurogenic inflammation. The neurogenic and neuropathic pain derives from the chemical reaction of the nerve and/or mechanical injuries of neuropeptide sensors. Neurogenic inflammation is an important element of several diseases such as rheumatoid arthritis, allergic contact dermatitis, psoriasis, asthma and inflammatory bowel diseases.

Sensory neuropeptides (e.g. substance P: SP, neurokinin A: NKA, calcitonin gene-related peptide: CGRP) are released from the activated nerves which cause vasodilatation, leakage of plasma protein, and abnormal innervation in the field of immune cells. These peptides, as well as the immune-cell derived mediators, sensitize the nerve endings which causes pain.

Neuropathic pain induced by peripheral nerve damage in cases of herpes zoster infection, HIV, nutritional deficiencies, toxins, malignancies, immune-mediated disorders and physical trauma to a nerve trunk, affects great number of patients, it is related to peripheral sensitization of the nerve endings and central sensitization of the secondary sensory neurones in the spinal cord.

The neurogenic inflammatory component of the above mentioned diseases is not eliminated by the conventional anti- inflammatory drugs (COX inhibitors), and glucocorticoids are only moderately effective and exert many severe side-effects which limit their clinical application.

Neuropathic pain is resistant to COX inhibitors or opioid analgesics, only certain anti-depressants or anti-epileptics (adjuvant analgesics) are moderately effective in some cases, but not in case of nerve trauma-evoked neuropathy.

Therefore, it is particularly important to identify novel therapeutical targets and mechanisms in

such conditions. Targeting the peptidergic sensory nerves and inhibiting their pathological activation and the release of pro-inflammatory sensory neuropeptide, might be a novel pathway to inhibit neurogenic inflammation and neuropathic pain. The university seeks research cooperation, partners for common development and out-licensing partners from all countries.

Advantages and Innovations

Identification of novel therapeutical targets and mechanisms which are targeting the peptidergic sensory nerves and inhibiting their pathological activation.

Stage of Development

Under development/lab tested

IPR Status

Patent(s) applied for but not yet granted

Profile Origin

National or Regional R&D programme

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : Yes

Client

Already Engaged in Trans-National Cooperation

Yes

Languages Spoken

English
Hungarian

Client Country

Hungary

Partner Sought

Type and Role of Partner Sought

The university seeks research cooperation, partners for common development and out-licensing partners from all countries.

Type of Partnership Considered

License agreement
Technical cooperation agreement
Research cooperation agreement

Technology Request

Looking for pre-diagnostic healthcare software / web platform which uses a smart electronic stethoscope's sound signal.

Summary

Spanish company producing medical devices with connection to smartphones and tablets has developed a smart electronic stethoscope. The company is looking for partners (companies, universities or research institutions) that are able to develop and/or provide a web platform/software for pre-interpreting pathologies using the stethoscope's audio signal to minimize diagnosis doubts. Technical cooperation and/or license agreement are sought.

Expiration Date 23 May 2017
Reference TRES20160520001

Details

Description

The company based in the Valencia region (Spain), is specialized in research and development of information technology (IT) to produce medical and veterinary devices with high measurement accuracy and connected to the latest mobile technologies (mHealth). The company has developed the first smart electronic stethoscope. It allows: a joint listening, recording the auscultation for the diagnosis follow-up or sharing it easily with other professionals. Data can be viewed through any smart device like tablets, smartphones and PCs. Unfortunately, nowadays, this stethoscope is not provided with intelligent software and algorithm based pre-diagnostic to help health's professionals in their diagnose process.
The inability to make clear diagnostics, or negative diagnosis so as to be assured of the absence of a pathology, means that health system could incur in unnecessary expenses. Currently, when a patient is referred to a specialist practitioner due to the inability of the primary health centre to make a negative diagnosis, there are 2 possible results: the patient actually has the pathology initially diagnosed and, therefore, the referral is correct; or the patient is healthy and therefore, the referral was not suitable generating then unnecessary expenses.
Therefore, the company wants to developed an intelligent system diagnosis platform (ISDP), capable of pre-interpreting the data offered by primary pre-diagnostic tool by comparing them with normal patterns and detecting any non-coincidence by raising an alarm and generating an electronic report. The target of this system will be to help professionals in their diagnosis providing them of support for more accuracy.
The company is looking for partners, in the sector of medical equipment / software, interested in developing this software able to expand the range of this medical device and/or provide the platform for health monitoring (ISDP) using the electronic stethoscope developed by the company. Potential partners should be interested to perform a technical cooperation and/or a license agreement.
Innovation, advantages and economoc benefits:
• At the present, there are no similar systems (ISDP) in the market. Related systems are only

being used based on large medical devices, mainly in the field of medical imagery, not including smaller equipment and diagnostics devices typically used in primary healthcare.
• It reduces costs at the sanitary health system because the system decreases the number of unnecessary referrals to the specialist practitioner.
• The system could be adapted for remote diagnose and assistance (telemedicine)
• The system could be used as first diagnose step in situ in emergency situations without the intervention of a specialist practitioner.

Technical Specification or Expertise Sought

The company seeks external support for the development of the algorithm through collaboration with: research organizations, universities and/or companies that develop and produce platform and/or software for health monitoring and telemedicine systems.
The system should be designed for a broad range of illness able to detected using stethoscope, not only for detecting heart murmurs specifically.
Technology Readiness Level (TRL) being equal to, or greater than, 4 ("validation in the laboratory") is required.

Stage of Development

Under development/lab tested

Comments Regarding Stage of Development

Technology Readiness Level (TRL) being equal to, or greater than, 4 ("validation in the laboratory") is required.

Network Contact

Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

Contact Person

María Fernández Santa Cruz Campos

Email

maria.fernandezsantacruz@juntadeandalucia.es

Open for EOI : Yes

Client

Already Engaged in Trans-National Cooperation

Yes

Languages Spoken

English
Spanish

Client Country

Spain

Partner Sought

Type and Role of Partner Sought

Type and role of partner sought:
• Medical equipment companies and/or manufacturers of portable medical devices with wireless technology interested to provide and/or develop web platform for healthcare.
• Software developers in healthcare sector.
• Research organization / universities interested in developing software for medical devices with wireless technologies that can help to the healthcare professionals in their diagnoses.

Potential partners should be interested to perform:
• Technical cooperation to develop and/or adapt existing software to the needs of the company. TRL should not be less than 4.
• License agreement of the software already developed and commercialised in the sector.

Type of Partnership Considered

License agreement
Technical cooperation agreement